At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 1 enrolled
Drug / intervention
C1-INH (Berinert)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Use of C1-INH (Berinert) for Renal Allograft Salvage in Refractory Antibody Mediated Rejection
In Brief
A Phase 2 clinical trial evaluating C1-INH (Berinert) for Antibody Mediated Rejection of Kidney Transplant. Completed, enrolled 1 participant across 1 site.
Detailed Summary
This is an open-label, single arm trial in which patient who have ongoing antibody mediated rejection of a kidney transplant deemed refractory to maximal medical therapy are given the complement inhibitor C1-INH (Berinert) in an effort to protect the graft from ongoing antibody mediated injury. A maximum of 5 patients will be enrolled.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsCSL Behring
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartOct 2016
First PostedOct 2016
Primary CompletionOct 2018
TodayJul 2026
First PostedOct 18, 2016
Enrollment StartOct 1, 2016
Primary CompletionOct 30, 2018
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 9.7 years ago
Interventions
C1-INH (Berinert)drug